A small-molecule therapy to reactivate the immunological response to cancer

Reference number 2018-04662
Coordinator IMMUNSCAPE AB
Funding from Vinnova SEK 500 000
Project duration December 2018 - June 2019
Status Completed

Purpose and goal

The development of difficult-to-treat cancer is characterized by the fact that the tumor cells inhibit the immune response of the patient thereby failing to remove the tumor. Immunscape has developed drug candidates that activate immune cells, thus regaining their ability to eliminate tumor cells. The goal of this grant was to find out the project´s commercial opportunities and to prepare it for clinical trials, which has also been done successfully.

Expected results and effects

The project has led us to identify critical steps for further development into clinical studies. The best drug candidates have been evaluated and the intangible position has been strengthened. The result of these activities has led to a collaboration being established with an investor who can finance the project into the clinical phase.

Planned approach and implementation

The project´s positioning towards current treatments has been evaluated and a business plan has been written by doing a market analysis and developing and establishing contacts with potential buyers of the project to test our concept. This together with discussions with preclinical and clinical development actors have helped us to establish plans for preclinical safety studies and a phase 1/2 clinic program.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.